Overview Indication Pharmacokinetics Pharmacodynamics Mode of action Adverse reactions Precautions/contraindication References
ChemicalBook > CAS DataBase List > Levonorgestrel

Levonorgestrel

Overview Indication Pharmacokinetics Pharmacodynamics Mode of action Adverse reactions Precautions/contraindication References
Product Name
Levonorgestrel
CAS No.
797-63-7
Chemical Name
Levonorgestrel
Synonyms
L-NORGESTREL;levonova;Levonorgestrel for system suitability 1 CRS;wy-5104;postinor;Microlut;Microval;norplant2;Levonelle;Norgeston
CBNumber
CB7125746
Molecular Formula
C21H28O2
Formula Weight
312.45
MOL File
797-63-7.mol
More
Less

Levonorgestrel Property

Melting point:
206°C
alpha 
D20 -32.4° (c = 0.496 in CHCl3)
Boiling point:
392.36°C (rough estimate)
Density 
1.0697 (rough estimate)
refractive index 
1.4900 (estimate)
storage temp. 
Sealed in dry,2-8°C
solubility 
Practically insoluble in water, sparingly soluble in methylene chloride, slightly soluble in ethanol (96 per cent).
pka
13.09±0.40(Predicted)
form 
Solid
color 
Crystals from MeOH/CHCl3
Water Solubility 
10mg/L(temperature not stated)
Merck 
13,6736
BCS Class
1
InChI
InChI=1/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/s3
InChIKey
WWYNJERNGUHSAO-HABXDNTMNA-N
SMILES
C([C@]12CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]3([H])[C@]1([H])CC[C@@]2(O)C#C)C |&1:1,4,6,16,18,22,r|
CAS DataBase Reference
797-63-7(CAS DataBase Reference)
More
Less

Safety

Hazard Codes 
Xn,T
Risk Statements 
20/21/22-40-60
Safety Statements 
22-36
WGK Germany 
3
RTECS 
JF8225000
HS Code 
2937230000
Hazardous Substances Data
797-63-7(Hazardous Substances Data)
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Danger
Hazard statements

H351Suspected of causing cancer

H362May cause harm to breast-fed children

Precautionary statements

P202Do not handle until all safety precautions have been read and understood.

P260Do not breathe dust/fume/gas/mist/vapours/spray.

P263Avoid contact during pregnancy/while nursing.

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P308+P313IF exposed or concerned: Get medical advice/attention.

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
N2260
Product name
D(?)-Norgestrel
Purity
analytical standard
Packaging
1g
Price
$431
Updated
2024/03/01
Sigma-Aldrich
Product number
1362602
Product name
Levonorgestrel
Purity
United States Pharmacopeia (USP) Reference Standard
Packaging
125mg
Price
$436
Updated
2024/03/01
Cayman Chemical
Product number
10006318
Product name
Levonorgestrel
Purity
≥95%
Packaging
100mg
Price
$25
Updated
2024/03/01
Cayman Chemical
Product number
10006318
Product name
Levonorgestrel
Purity
≥95%
Packaging
500mg
Price
$107
Updated
2024/03/01
Sigma-Aldrich
Product number
Y0001618
Product name
Levonorgestrel for system suitability 2
Purity
European Pharmacopoeia (EP) Reference Standard
Packaging
y0001618
Price
$132
Updated
2024/03/01
More
Less

Levonorgestrel Chemical Properties,Usage,Production

Overview

Levonorgestrel[LNG] is a synthetic progestational hormone with actions similar to those of progesterone and about twice as potent as its racemic or[+-]-isomer[norgestrel][1]. It is a kind of emergency contraception, referring as a drug or device used to prevent pregnancy after unprotected sexual intercourse[including sexual assault] or after a recognized contraceptive failure[1]. It is used for contraception, control of menstrual disorders, and treatment of endometriosis. Levonorgestrel is marketed mostly as a combination oral contraceptive under several brand names such as Alesse, Triphasil, and Min-Ovral. It is also marketed under the brand of Plan B.
Levonorgestrel was discovered in 1963 and was introduced for medical use together with ethinylestradiol in 1970.[2, 3] It is listed as an essential medicine by the World Health Organization, being the most effective and safe medicines needed in a health system.[4] It is available as a generic medication.[5]
Levonorgestrel is a levo-isomer of Norgestrel. The progestins include the naturally occurring hormone progesterone, 17a-acetoxyprogesterone derivatives in the pregnane series, 19-nortestosterone derivatives(estranes), and norgestrel and related compounds in the gonane series. The 19-nortestosterone derivatives were developed for use as progestins in oral contraceptives, and while their predominant activity is progestational, they exhibit androgenic and other activities. The gonanes are a more recently developed series of “19-nor” compounds, containing an ethyl rather than a methyl substituent in the 13-position, and they have diminished androgenic activity[6].

Figure 1. The chemical structure of levonorgestrel

Indication

Levonorgestrel is a progestin-only emergency contraceptive indicated for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. To obtain optimal efficacy, its should be taken as soon as possible within 72 hours of intercourse. In US, it(Plan B) is available only by prescription for women younger than age 17 years, and available over the counter for women 17 years and older. However, it should be noted that it is not indicated for routine use as a contraceptive[7].

Pharmacokinetics

Progesterone is rapidly absorbed following administration by any route. Its half-life in the plasma is approximately 5 minutes, and small amounts are stored temporarily in body fat. It is almost completely metabolized in liver to pregnanediol and conjugated with glucuronic acid. It is excreted into the urine as pregnanediol glucuronide. Most of the synthetic progestins are extensively metabolized to inactive products that are excreted mainly in the urine. Route of administration of levonorgestrel is oral. Duration of action is 1-3 days. It has Androgenic, Antiestrogenic and Anabolic activities[8]. The synthetic progestins have much longer half-lives, e.g., approximately 7 hours for norethindrone, 16 hours for norgestrel, 12 hours for gestodene, and 24 hours for MPA[6].

Pharmacodynamics

Levonorgestrel is a synthetic form of the naturally occurring female sex hormone, progesterone[1]. The physiological effect of progesterone is as below[1]: during woman's normal menstrual cycle, an egg matures and is released from the ovaries[ovulation]. The ovary then produces progesterone to prevent the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Levonorgestrel tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries.

Mode of action

LNG can prevent pregnancy several different ways, depending on the cycle day of unprotected sex and the day on which treatment is initiated[9]. To be effective, postcoital treatment should inhibit or delay ovulation or inhibit implantation. If sexual intercourse takes place shortly before or at the time of ovulation, and treatment is given after ovulation, an inhibitory effect on embryo development or implantation is necessary to prevent pregnancy. How LNG prevents pregnancy in the doses used for EC is not known[10]. However, emergency contraceptives do not interrupt pregnancy after implantation[6].
Effects on the ovulatory process:
LNG, 0.75 mg, in repeated doses has been shown to suppress proliferative activity of the endometrium when administered during the follicular phase. It suppresses ovarian function when administered in the late follicular phase and around the time of ovulation. No significant endometrial changes were detected when LNG was administered in the secretory phase. However, ovulation process is the main target for emergency contraception[10].
Effects on the endometrium:
High dose ethinyl estradiol –norgestrel ECPs effectively suppresses progesterone associated endometrial protein in the midluteal uterus, potentially altering the endometrial environment unfavorably and affecting the survival of the early embryo[20]. LNG existing evidence does not support the hypothesis that it alters endometrial receptivity or impedes implantation. From a physiological and pharmacological point of view, the administration of synthetic progestogens such as LNG is highly unlikely to reduce endometrial receptivity. Progestogens, whether natural or synthetic, are so called because of their ability to sustain pregnancy in ovariectomised animals[11]. The 25% failure rate of EC and the fact that it works best when used soon after sexual intercourse[12] are further reasons for doubting that this method impedes pregnancy by interference with postfertilisation events.
Effects on the migration and function of spermatozoa:
LNG has some experimental evidence for transportation of spermatozoa from the vagina to the fallopian tube. Administration of 400 μg LNG(57% of the current LNG dosage) 3–10 hours after sexual intercourse affected sperm migration between 3 and 9 hours after treatment. It reduced the number of spermatozoa recovered from the uterine cavity, increased the pH of the uterine fluid(which immobilized spermatozoa), and increased the viscosity of cervical mucus(which impeded further passage of sperm cells into the uterine cavity)[13]. These results are highly relevant to the actions of LNG used as an EC.

Adverse reactions

Side effects are medically minor but troublesome to the patients. No deaths or serious complications have been causally linked to LNG.
Nausea and vomiting: The main side effects are gastrointestinal. The Yuzpe regimen causes nausea in up to 50% of recipients and as many as 19% experience vomiting. Since the pills are completely absorbed within one hour, replacement dosing is unnecessary if vomiting occurs after this time. The LNG regimen is significantly better tolerated, with nausea in 23% and vomiting 6%[14]. Meclizine is effective for preventing nausea and vomiting associated with the Yuzpe regimen of LNG[15].
Other common side effects with LNG regimens are dizziness, fatigue, headache, breast tenderness, lower abdominal pain and menstrual irregularities[14]. Although some women may experience spotting, the majority of women have their menstrual period on time or slightly early[16].
Risk of Ectopic pregnancy: Camp S.L. et al. has calculated from various clinical trials of 0.75 mg tablets of LNG used for EC(including almost 6000 women), 98 pregnancies were reported; 1 of which was ectopic, giving an ectopic pregnancy rate of 1%[9], i.e. we cannot deny a risk of ectopic pregnancy.
Teratogenic Effects: The limited data on teratogenic effects come from a relatively small number of reports in which treatment was not successful, and the woman elected to continue the pregnancy. No evidence exists of a specific syndrome of anomalies or an apparent increase in the incidence of anomalies. It is important to recognize that no studies have investigated teratogenic effects associated with the use of oral emergency contraception[17].

Precautions/contraindication

Women do not need provider intervention to use the LNG regimen of ECPs safely and effectively[18]. Progestogens only can be started in healthy non-pregnant women without screening procedures. According to WHO international guidelines, the minimum requirements before starting contraception with a combined estrogen -progestogens product consists of asking for a personal and family history of deep vein thrombosis and measuring blood pressure at baseline and follow-up. Combined agents are best avoided by women over 35 years who smoke[19]. If normal menstrual bleeding does not occur within 21 days after taking LNG or by 28 days if an oral contraceptive was initiated after LNG use, a pregnancy test should be taken[20].
Levonorgestrel is safe—even if taken in pregnancy, evidence suggests that it will not harm the pregnancy or the fetus —and it has no potential for addiction. The regimen has few contraindications, all of which should be easy for the consumer to identify for herself without needing an examination[21]. There are only three contraindications to the use of LNG as EC: existing pregnancy, undiagnosed vaginal bleeding or a known allergy to any ingredient in the product[9]. There are no absolute medical contraindications to the use of emergency contraception with the exception of pregnancy, and this is only because it is ineffective. According to WHO there are no known medical contraindications to the use of hormonal EC, aside from allergy to one of the constituents[22].

References

  1. https://www.drugbank.ca/drugs/DB00367
  2. https://books.google.com/books?id=ja2nBgAAQBAJ&pg=PA383
  3. https://books.google.com/books?id=FsKpBAAAQBAJ&pg=PA77
  4. http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1
  5. https://books.google.ca/books?id=BwqEAgAAQBAJ&pg=PA310
  6. David SL, George MS. Estrogens and Progestins. In: Laurence L. Brunton, John S. Lazo, Keith L. Parker Goodman & Gilman’s the pharmacological basis of therapeutics – 11th edition. New York: McGraw-Hill Medical Publishing Division; 2006. 1541-1571.
  7. https://www.rxlist.com/plan-b-drug.htm#description
  8. Chrousos GP. The Gonadal Hormones and Inhibitors. In: Katzung BG. Editors. Basic and Clinical Pharmacology. 9th International edition, Boston, New York, New Delhi, McGrawHill Companies Inc 2004: 661-692.
  9. Camp SL, Wilkersona DS, Raine TR. The benefits and risks of over-the-counter availability of Levonorgestrel emergency contraception. Contraception 2003; 68: 309–317.
  10. Marions L, Hultenby K, Lindell I, Sun X, Stabi B, Danielsson KG. Emergency Contraception with Mifepristone and Levonorgestrel: Mechanism of Action. Obstet Gynecol 2002; 100[1]:65–71
  11. Croxatto HB. Emergency contraception pills: how do they work? IPPF Medical Bulletin 2002; 36[6]: 1-2.
  12. Piaggio G, Von Hertzen H, Van Look PFA. Timing of emergency contraception with levonorgestrel or the Yuzpe regimen. Lancet 1999; 353: 721.
  13. Kesseru E, Garmendia F, Westphal N, Parada J. The hormonal and peripheral effects of dlnorgestrel inpostcoital contraception. Contraception 1974; 10:411-24.
  14. Task Force on Postovulatory Methods of Fertility Regulation. Randomized controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998; 352: 428–33.
  15. Raymond EG, Creinin MD, Barnhart KT, Lovvorn AE, Rountree RW, Trussell J. Meclizine for Prevention of Nausea Associated With Use of Emergency Contraceptive Pills: A Randomized Trial. Obstet Gynecol 2000; 95[2]: 271–277.
  16. Glasier A,Thong KJ, et al. Mifepristone[RU 486] compared with high dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med 1992; 327:1041-4.
  17. Weismiller DG. Emergency Contraception. Am Fam Physician 2004; 70[4]:707-14.
  18. Raymond EG, Chen PL, Dalebout SM. “Actual Use” Study of Emergency Contraceptive Pills Provided in a Simulated Over-the-Counter Manner. Obstet Gynecol 2003; 102[1]:17–23.
  19. Amy JJ, Tripathi V. Contraception for women: an evidence based overview. BMJ 2009; 339: b 2895.
  20. Kleppin S. Levonorgesterel for Emergency Contraception: Controversy continues regarding Plan B. JPSW 2006; 21-23
  21. Raymond EG, Dalebout SM, Camp SI. Comprehension of a Prototype Over-the-Counter Label for an Emergency Contraceptive Pill Product. Obstet Gynecol 2002; 100[2]:342–9.
  22. Dunn S, Guilbert E. Emergency Contraception. J Obstet Gynaecol Can 2003; 25[8]:673–9.

Description

Levonorgestrel exhibits some androgenic activity but no glucocortic oid or antimineraloc orticoid action. Levonorgestrel can be administered orally, transdermally (combined with estradiol and formulated as a 7-day patch), and for prolonged, continuous use, via an intrauterine device (IUD). The oral bioavailability of levonorgestrel is approximately 95%. From a protein binding pers pective, 48% of an oral dose is bound to SHBG, and 50% is bound to albumin. Levonorgestrel under goes metabolic reduction of its ketone and is hydroxylated.

Chemical Properties

White Solid

Originator

Ovrette,Wyeth,US,1968

Uses

D-(-)-Norgestrel is an emergency contraceptive. Levonorgestrel is safe, tolerated and effective in emergency contraception in woman. Norgestimate USP Related Compound A.

Uses

progestin

Definition

A synthetic steroid hormone used as an ingredient of oral contraceptives. Approved by FDA.

Manufacturing Process

To 0.7 gram of (+/-)-1,4-dihydro-17α-ethynyl-18-homo-oestradiol 3-methyl ether in 36 cc methanol was added 1.6 cc water and 2.4 cc concentrated hydrochloric acid. After standing at room temperature for 2 hours ether was added, and the washed and dried ethereal solution was evaporated, yielding a gum which was dissolved in 5 cc benzene and the solution absorbed on 50 grams of an activated fuller's earth. Elution with light petroleum containing increasing proportions of benzene gave a crystalline by-product: further elution with benzene containing a small proportion of ether gave a crystalline product which was recrystallized from ethyl acetate, yielding 0.11 gram of (+/-)-17α-ethynyl-18-homo-19-nortestosterone. MP 203° to 206°C.

brand name

Mirena (Berlex); Norplant (Wyeth); Plan B (Duramed).

Therapeutic Function

Progestin

Safety Profile

Human reproductive effects byingestion: menstrual cycle changes, fertility index.Questionable carcinogen with experimental neoplastigenicdata. When heated to decomposition it emits acrid smokeand irritating fumes.

Levonorgestrel Preparation Products And Raw materials

Raw materials

Tetrahydrofuran Diethyl ether

Preparation Products

More
Less

Levonorgestrel Suppliers

Canada 2 China 316 Europe 3 France 1 Germany 2 Hungary 2 India 18 Italy 3 Japan 1 Switzerland 1 United Kingdom 6 United States 31 Global 386
Wuhan DKY Technology Co.,Ltd.
Tel
27-81302488 18007166089
Fax
027-81302088
Email
info@dkybpc.com
Country
China
ProdList
2024
Advantage
58
Yunfei Pharmaceutical(Shenzhen) Co., Ltd.
Tel
0755-61160828 15994832653
Fax
0755-61160828
Email
hulixiu@yunfeipharma.com
Country
China
ProdList
248
Advantage
58
Hubei Xingcheng Biotechnology Co., Ltd
Tel
19171210221
Fax
QQ:3505191060
Email
3371991952@qq.com
Country
China
ProdList
957
Advantage
58
Nanjing Shizhou Biotechnology Co., Ltd
Tel
025-85563444 15850508050
Fax
18013869214
Email
rose.shi@synzest.com
Country
China
ProdList
269
Advantage
58
Wuhan Wiseman Bioengineering Co.,Ltd
Tel
027-59506022 13419526507
Fax
027-59506022
Email
13419526507@163.com
Country
China
ProdList
2992
Advantage
58
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
021-61259108 18621169109
Fax
86-21-61259102
Email
market03@meryer.com
Country
China
ProdList
40228
Advantage
62
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Fax
021-58180499
Email
sales@BioChemBest.com
Country
China
ProdList
6005
Advantage
61
TCI (Shanghai) Development Co., Ltd.
Tel
021-67121386
Fax
021-67121385
Email
Sales-CN@TCIchemicals.com
Country
China
ProdList
24529
Advantage
81
Chemsky（shanghai）International Co.,Ltd.
Tel
021-50135380
Email
shchemsky@sina.com
Country
China
ProdList
32321
Advantage
50
Tianjin heowns Biochemical Technology Co., Ltd.
Tel
400 638 7771
Email
sales@heowns.com
Country
China
ProdList
14435
Advantage
57
Sinopharm Chemical Reagent Co,Ltd.
Tel
86-21-63210123
Fax
86-21-63290778 86-21-63218885
Email
sj_scrc@sinopharm.com
Country
China
ProdList
9815
Advantage
79
Spectrum Chemical Manufacturing Corp.
Tel
021-021-021-67601398-809-809-809 15221380277
Fax
021-57711696
Email
marketing_china@spectrumchemical.com
Country
China
ProdList
9658
Advantage
60
Wuhan Fortuna Chemical Co., Ltd
Tel
027-59207852 13308628970
Fax
QQ3130921841
Email
buy@fortunachem.com
Country
China
ProdList
2866
Advantage
58
S.Z. PhyStandard Bio-Tech. Co., Ltd.
Tel
0755-83725681-603
Fax
+86 755 28094224
Country
China
ProdList
4496
Advantage
50
Shanghai civi chemical technology co.,Ltd
Tel
86-21-34053660
Fax
86-21-34053661
Email
sale@labgogo.com
Country
China
ProdList
9865
Advantage
52
Beijing HuaMeiHuLiBiological Chemical
Tel
010-56205725
Fax
010-65763397
Email
waley188@sohu.com
Country
China
ProdList
12335
Advantage
58
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Fax
(86) 21-58955996
Email
info@chemexpress.com
Country
China
ProdList
7552
Advantage
61
9ding chemical ( Shanghai) Limited
Tel
4009209199
Fax
86-021-52271987
Email
sales@9dingchem.com
Country
China
ProdList
22514
Advantage
55
Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
400-400-6206333 18521732826
Fax
021-50323701
Email
market@aladdin-e.com
Country
China
ProdList
25003
Advantage
65
Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399 18927568969
Fax
020-39119999
Email
isunpharm@qq.com
Country
China
ProdList
4674
Advantage
55
Nanjing Sunlida Biological Technology Co., Ltd.
Tel
025-57798810
Fax
025-57019371
Email
sales@sunlidabio.com
Country
China
ProdList
3239
Advantage
55
TargetMol Chemicals Inc.
Tel
021-021-33632979 15002134094
Fax
021-33632979
Email
marketing@targetmol.com
Country
China
ProdList
7783
Advantage
58
Shanghai BeiZhuo Biotech Co., Ltd.
Tel
021-61119791,13386096464
Fax
021-50190009
Email
bzswkf@foxmail.com
Country
China
ProdList
3921
Advantage
50
Hubei XinyuanShun Chemical Co., Ltd.
Tel
13971561712, 13995564702, 027-50664929
Fax
027-50664927
Email
hbeixys2001@163.com
Country
China
ProdList
3120
Advantage
55
ChemStrong Scientific Co.,Ltd
Tel
0755-0755-66853366 13670046396
Fax
0755-28363542
Email
sales@chem-strong.com
Country
China
ProdList
18070
Advantage
56
Sichuan Wei Keqi Biological Technology Co., Ltd.
Tel
028-81700200 18116577057
Fax
028-81705658
Email
3003855609@qq.com
Country
China
ProdList
7887
Advantage
56
Wuxi Zhongkun Biochemical Technology Co., Ltd.
Tel
0510-85629785 18013409632
Fax
051085625359
Email
sales@reading-chemicals.com
Country
China
ProdList
15178
Advantage
58
Shanghai CanSpecsci Instrument Co., Ltd.
Tel
400-6087598 15021221957
Fax
4006087598-8012
Email
order@canspecsci.com
Country
China
ProdList
2045
Advantage
56
Wuhan Dahua Pharmaceutical Co., Ltd.
Tel
027-59262863 13277907145 3091977954
Fax
027-59420980
Country
China
ProdList
4943
Advantage
58
Shanghai Macklin Biochemical Co.,Ltd.
Tel
15221275939 15221275939
Fax
021-50706099
Email
shenlinxing@macklin.cn
Country
China
ProdList
16166
Advantage
55
Shanghai HuanChuan Industry Co.,Ltd.
Tel
021-61478794
Fax
021-61478794
Email
sales@hcshhai.com
Country
China
ProdList
9793
Advantage
50
Wuhan Dahua Weiye Pharmaceutical Chemical Co., Ltd.
Tel
027-59420981,18702770802
Fax
027-83322098
Country
China
ProdList
1975
Advantage
50
Shanghai Yongye Biotechnology Co., Ltd.
Tel
86-021-61559134 15921386130
Fax
021-55068248
Email
3423497944@qq.com
Country
China
ProdList
8144
Advantage
55
AdooQ Bioscience CHINA
Tel
025-58849295 18951903616;
Fax
025-68650336
Email
info@adooq.cn
Country
China
ProdList
2990
Advantage
60
Credit Asia Chemical Co., Ltd.
Tel
+86 (21) 61124340
Fax
+86 (21) 6129-4103
Country
China
ProdList
9756
Advantage
58
Chizhou Kailong Import and Export Trade Co., Ltd.
Tel
Fax
-
Email
xg01_gj@163.com
Country
China
ProdList
9484
Advantage
50
Watson Biotechnology Co.,Ltd
Tel
027-59207879 1972026995 18140587686
Fax
QQ：1972026995
Email
sales@3600chem.com
Country
China
ProdList
4661
Advantage
55
Alta Scientific Co., Ltd.
Tel
022-6537-8550 15522853686
Fax
022-2532-9655
Email
sales@altasci.com.cn
Country
China
ProdList
4511
Advantage
55
Wuhan Senwayer Century Chemical Co.,Ltd
Tel
027-86652399 13627115097;
Fax
86-27-59707018
Email
sales@senwayer.com
Country
China
ProdList
267
Advantage
55
Shanghai Send Pharmaceutical Technology Co., Ltd.
Tel
021-58088081 Q3382968513
Fax
QQ3382968513
Email
hailey@shsendpharm.com
Country
China
ProdList
3126
Advantage
55
Jinan Putubio Tech Co., Ltd.
Tel
+86 (531) 8099-2215
Fax
+86 (531) 8099-2215
Email
putubio@outlook.com
Country
China
ProdList
1261
Advantage
55
Artis Biotech Co. Ltd.
Tel
0575-18780151478 18582380095
Fax
0575-89298961
Email
sales@artisbio.com
Country
China
ProdList
2966
Advantage
58
Boen pharm
Tel
86 512-62572107 62962707
Fax
86 512-62922078
Country
China
ProdList
800
Advantage
58
Beijing Cooperate Pharmaceutical Co.,Ltd
Tel
+86-010-60279497 +86-15646567669
Fax
010-60279497
Email
sales01@cooperate-pharm.com
Country
China
ProdList
137
Advantage
58
Guangzhou QiYun Biotechnology Co., Ltd.
Tel
020-61288194 61288195
Fax
020-61288700
Email
505721671@qq.com
Country
China
ProdList
3866
Advantage
58
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
27313
Advantage
60
Shanghai QianYan Bio-technology Co., Ltd
Tel
02781293128
Email
orders@biochemsafebuy.com
Country
China
ProdList
9923
Advantage
55
Raw material medicin reagent co.,Ltd
Tel
Email
sales@njromanme.com
Country
China
ProdList
4529
Advantage
58
Chengdu Dianchun Technology Co., Ltd
Tel
400-1166-196 18502815961
Fax
QQ：800101999
Email
cdhxsj@163.com
Country
China
ProdList
14603
Advantage
60
More
Less

View Lastest Price from Levonorgestrel manufacturers

Hebei Zhuanglai Chemical Trading Co Ltd
Product
Levonorgestrel 797-63-7
Price
US $79.00-38.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
20ton
Release date
2024-11-19
Wuhan Fortuna Chemical Co.,Ltd
Product
Levonorgestrel 797-63-7
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
50
Release date
2024-08-01
Wuhan Haorong Biotechnology Co.,Ltd
Product
Levonorgestrel 797-63-7
Price
US $0.00-0.00/KG
Min. Order
1KG
Purity
99%
Supply Ability
5000
Release date
2023-07-27

797-63-7, LevonorgestrelRelated Search:

Ethyl cellulose Ethyl formate Ethylbenzene CHLOROETHANE Ethylparaben Ethyl acetate Ethyl acrylate Ethanol EP Levonorgestrel Impurity B,13-Ethyl-17-hydroxy-18,19-dinor-17a-pregn-5(10)-en-20-yn-3-one(Levonorgestrel Impurity B) Ulipristal Acetate (9R,10R,13S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,9,10,11,12,15,16-decahydrocyclopenta[a]phenanthren-3-one ORITAVANCIN Levodopa (±)-13-ethyl-3-methoxy-18,19-dinor-17alpha-pregna-2,5(10)-dien-20-yn-17-ol 13-Ethyl-18,19-dinor-17a-pregn-4-en-20-yn-17-ol(Levonorgestrel Impurity D),EP Levonorgestrel Impurity D (R)-(+)-Dropropizine Levosimendan Potassium (R)-[(3-ethoxy-1-methyl-3-oxoprop-1-enyl)amino]phenylacetate

  • 13-ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one
  • 13-ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one
  • 13-ethyl-17-hydroxy-19-dinor-17-alpha-pregn-4-en-20-yn-3-on(+)-1
  • 17-alpha-ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one
  • microluton
  • norplant2
  • norplantii
  • postinor
  • wy-5104
  • L-NORGESTREL
  • D(minus)-norgestrel
  • Norgestrel (L-)
  • 13β-ethyl-17α-ethynyl-17β-hydroxygon-4-en-3-one
  • LEVONORGESTEREL,USP
  • D(-)-13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
  • Levonorgestrel
  • (8S,9S,13S,14S,17S)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol
  • Levonorgestre
  • (17α)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-yn-3-one
  • 17-beta-hydroxy-18-methyl-19-nor-17-alpha-pregn-4-en-20-yn-3-one
  • 17-ethynyl-18-methyl-19-nortestosteron
  • 17-ethynyl-18-methyl-19-nortestosterone
  • 18-methyl-17-alpha-ethynyl-19-nortestosterone
  • 18-methylnorethindrone
  • follistrel
  • levonova
  • LEVONORGESTREL (D-(-)-NORGESTREL)
  • Dexnorgestrel
  • Levonelle
  • Microlut
  • Microval
  • Norgeston
  • 17-Beta-Hydroxy-18-Me
  • (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one
  • Levonorgestrel (200 mg)
  • Levonorgestrel(Levonelle)
  • 17-Ethynyl-18-Methyl-
  • (-)-Levonorgestrel (-)-17alpha-Ethynyl-18-methyl-19-nortestosterone (-)-18,19-Dinor-13beta-ethyl-17beta-hydroxy-4-pregnen-20-yn-3-one
  • Levinirgestrel
  • Gestrinone Impurity 5
  • 13-ethyl-17-hydroxy-, (17α)-18,19-Dinorpregn-4-en-20-yn-3-one
  • Levonorgestrel for system suitability 2
  • Levonorgestrel (125 mg)
  • D-(-)-norgestrel solution,100ppm
  • D-(-)-Norgestrel (Levonorgestrel)
  • Levonorgestrel(797-63-7)
  • [18,19-Dinorpregn-4-en-20-yn-3-one-13-ethyl-17-hydroxy-,(17.α.)-(-)-]
  • Levonorgestrel for system suitability 1 CRS
  • (-)-Norgestrel&gt
  • Levonorgestrel for system suitability 2 CRS
  • 97.0%(GC&amp
  • Levonorgestrel CRS
  • 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17α)-
  • (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
  • (-)-17alpha-Ethynyl-18-methyl-19-nortestosterone
  • (-)-18,19-Dinor-13beta-ethyl-17beta-hydroxy-4-pregnen-20-yn-3-one
  • (-)-Levonorgestrel
  • Levonorgestrel USP/EP/BP